Fast-Growing AstraZeneca Brushes Off China Rumors And Dato-DXd Concerns
Totality Of Data Will Reassure, Claims CEO
The company exceeded revenue and profit expectations in Q2, but sought to calm concerns about a rumored China spin-out and underwhelming Phase III data.
